



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Ojemda Page: 1 of 2

Effective Date: 8/13/2025 Last Review Date: 7/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

**Intent:**

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Ojemda under the patient’s prescription drug benefit.

**Description:**

FDA-Approved Indication

Treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

All other indications are considered experimental/investigational and not medically necessary.

**Applicable Drug List:**

Ojemda

**Policy/Guideline:**

**Documentation**

Submission of the following information is necessary to initiate the prior authorization review: medical record documentation of activating BRAF alteration

**Coverage Criteria**

Central Nervous System Cancer<sup>1</sup>

Authorization of 12 months may be granted for treatment of members 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

**Continuation of Therapy**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication in the Coverage Criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

**Approval Duration and Quantity Restrictions:**

**Initial and Renewal Approval:** 12 months

**Quantity Level Limit:** Maximum dose is 600mg once weekly.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Ojemda Page: 2 of 2

Effective Date: 8/13/2025 Last Review Date: 7/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input checked="" type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

**References:**

1. Ojemda [package insert]. Brisbane, CA: Day One Biopharmaceuticals, Inc.; June 2024.